Videos

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

Linda T. Vahdat, MD, discusses research with copper depletion in patients with high-risk triple-negative breast cancer.

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing challenges in determining the optimal treatment strategy for patients with early-stage breast cancer.

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer

Linda T. Vahdat, MD, discusses the use of ADCs in metastatic TNBC and how neoadjuvant immunotherapy performs in patients with early-stage TNBC.

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

A panel of experts offer future perspectives in HR+ breast cancer.

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.